Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | VCP | P55072 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20550423 | 0.90 | BMP1 (0.38) | GSK3BDYRK1AFAAHGRM5MEN1 | |
| SCHEMBL17769695 | 0.90 | WNT3A (0.38) | GSK3BDYRK1AFAAHGRM5TRPV1 | |
| SCHEMBL17778461 | 0.90 | WNT3A (0.38) | GSK3BDYRK1AFAAHGRM5TRPV1 | |
| SCHEMBL17618510 | 0.89 | PIK3CA (0.41) | GSK3BDYRK1AFAAHGRM5MEN1 | |
| SCHEMBL17778463 | 0.87 | FAAH (0.39) | GSK3BDYRK1AFAAHGRM5MEN1 | |
| SCHEMBL17778647 | 0.86 | GSK3B (0.38) | GSK3BDYRK1AFAAHGRM5TRPV1 | |
| SCHEMBL17778763 | 0.86 | GSK3B (0.39) | GSK3BDYRK1AGRM5TRPV1VCP | |
| SCHEMBL17767967 | 0.86 | GSK3B (0.39) | GSK3BDYRK1AGRM5TRPV1VCP | |
| SCHEMBL17778467 | 0.86 | MTOR (0.46) | FAAH | |
| SCHEMBL17768096 | 0.85 | VCP (0.39) | GSK3BDYRK1AGRM5TRPV1VCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180319810-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2018-11-08 | — | — | US | disclosed |
| WO-2016079712-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180319810-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | GSK3B 2340/4885DYRK1A 2959/4885FAAH 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.